Significant Transactions (Details 2) - USD ($) |
6 Months Ended | 12 Months Ended | |
|---|---|---|---|
Jan. 15, 2020 |
Dec. 31, 2020 |
Jun. 30, 2020 |
|
| Business Acquisition [Line Items] | |||
| Total estimated fair value of consideration | |||
| Solo Sciences, Inc. [Member] | |||
| Business Acquisition [Line Items] | |||
| Common shares issued | $ 17,550 | ||
| Contingent consideration | 389 | ||
| Total estimated fair value of consideration | $ 17,939 | $ 0 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|